<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31792">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925118</url>
  </required_header>
  <id_info>
    <org_study_id>H-1305-6130491</org_study_id>
    <nct_id>NCT01925118</nct_id>
  </id_info>
  <brief_title>Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2</brief_title>
  <official_title>Phase II Study of Irradiated Donor Lymphocyte Infusion Plus High-dose Interleukin-2 in Patients With Metastatic Malignant Melanoma and Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Partially HLA-matched irradiated donor lymphcyte infusion alone resulted in 27% overall
      response rate (ORR) in advanced renal cell carcinoma without significant toxicities. In
      addition, high-dose interleukin-2 (IL-2)showed an ORR of 6-21% in metastatic melanoma or
      renal cell carcinoma with a durable response in patients who achieved complete remission.
      Therefore, irradiated donor lymphocyte infusion plus high-dose IL-2 might show a synergistic
      anti-tumor activity agaist relapsed or metastatic melanoma or renal cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>12-week modified immune-related response rate</measure>
    <time_frame>12-week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-week modified immune-related response rate</measure>
    <time_frame>6-week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate based on RECIST v1.1</measure>
    <time_frame>6/12-week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6-month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1-year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-related adverse events</measure>
    <time_frame>12-week</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Malignant Melanoma and Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>High-dose IL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Irradiated donor lymphocyte infusion</intervention_name>
    <arm_group_label>High-dose IL-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed malignant melanoma or renal cell carcinoma

          -  At stage IV or relapse

          -  At least one prior chemotherapy including targeted agents

          -  At least one haploidential or partially matched-HLA donor

          -  ECOG performance status 0-1

          -  Age 18-75 years

          -  Measurable lesion

          -  Adequate bone marrow, liver, and renal functions

        Exclusion Criteria:

          -  Chemotherapy within 4 weeks

          -  Stem cell transplantation

          -  Active CNS metastasis

          -  Hypersensitivity to IL-2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dae Seog Heo, MD, PhD</last_name>
    <email>heo1013@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tae Min Kim, MD, PhD</last_name>
    <email>gabriel9@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae Seog Heo, MD, PhD</last_name>
      <email>heo1013@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dae Seog Heo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>August 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Dae Seog Heo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
